Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Calcium Hydroxybenzene Sulphonate Dispersible Tablets in Healthy Volunteers
NCT05794919Phase 1Unknown
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calcium dobesilate in chronic venous insufficiency (CVI) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Maximum Plasma Concentration at 36 hours, Area Under the Curve from time 0 to t at 36 hours and 1 more. Status: unknown.
02
Drugs
calcium dobesilate
03
Conditions
chronic venous insufficiency (CVI)
Beyond the preview
Go deeper on NCT05794919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05794919.